Head-to-head · WeighScore
LaSara Medical Group vs Zealthy
By GLP-1 ScorecardUpdated
Score comparison
LaSara Medical Group has the higher recorded score — 54.5/100 to 46.7/100.
LaSara Medical Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. LaSara Medical Group is a national telehealth provider with in-person availability in southern California, offering compounded semaglutide and tirzepatide alongside a broader menu of TRT, NAD+, sermorelin, B12, and enclomiphene — a multi-modality clinic rather than a pure GLP-1 platform.
Before you choose
Before comparing the headline prices, the LaSara Medical Group review and the Zealthy review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Apex MD vs LaSara Medical Group and Ondra Health vs Zealthy compare each of them with another graded program, and the list of alternatives to LaSara Medical Group ranks the programs closest to LaSara Medical Group on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the SnagRx review covers one graded close to these two, at 57.9/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | LaSara Medical Group | Zealthy |
|---|---|---|
| WeighScore | 54.5/100 | 46.7/100 |
| Grade | C | C |
| Site position | #485 | #512 |
| Semaglutide | $289/mo (compounded) | $151/mo on a 3-month supply, plus a separate membership (bundle $217 first month, then $297/mo; compounded) |
| Tirzepatide | $399/mo (bundle, compounded) | From $216/mo, plus a separate membership (bundle $349 first month, then $449/mo; compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Multi-modality clinic — compounded GLP-1s alongside TRT, peptides, B12, NAD+, sermorelin, and enclomiphene
- National telehealth plus an in-person option in Southern California — uncommon hybrid model
- Free initial consultation
- Active promotional pricing (30% off sitewide at the time of review)
- GLP-1 pricing now published on product pages: compounded semaglutide from $233/mo, tirzepatide from $325/mo on annual bundles
What to consider
- Legal entity name and state of incorporation not disclosed
- Compounding pharmacy partner not named
- LegitScript certification status not confirmed
- Per-state availability not listed despite the national-telehealth claim
- Lab work and ongoing monitoring inclusion not clearly disclosed for the multi-modality menu
FDAWarning letter issued to FitRX, LLC dba Zealthy in September 2025. See the FDA warning-letter database.
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
What to consider
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued FitRX, LLC dba Zealthy a warning letter in September 2025; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.